國家衛生研究院 NHRI:Item 3990099045/8635
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856848      Online Users : 938
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/8635


    Title: Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus
    Authors: Tseng, CH
    Contributors: Division of Environmental Health and Occupational Medicine
    Abstract: BACKGROUND: Whether metformin therapy affects ovarian cancer risk in Asian patients with type 2 diabetes mellitus (T2DM) has not been investigated. METHODS: Data analysis was performed in 2014. The reimbursement databases of Taiwanese female patients with a new diagnosis of T2DM between 1998 and 2002 (n = 479475) were retrieved from the National Health Insurance for follow-up of ovarian cancer until the end of 2009. Metformin was treated as a time-dependent variable; and of these patients, 286106 were never-users and 193369 were ever-users. A time-dependent approach was used to calculate ovarian cancer incidence and estimate hazard ratios by Cox regression for never-users (as referent group), ever-users, and subgroups of metformin exposure (tertiles of cumulative duration and cumulative dose). RESULTS: During follow-up, 601 metformin ever-users and 2600 never-users developed ovarian cancer, representing an incidence of 49.4 and 146.4 per 100,000 person-years, respectively. The overall fully adjusted hazard ratio (95% confidence intervals) for ever- versus never-users was 0.658 (0.593-0.730). The fully adjusted hazard ratios for the first, second, and third tertiles of cumulative duration of metformin therapy were 1.169 (1.019-1.341), 0.761 (0.644-0.898) and 0.276 (0.225-0.340), respectively (P-trend <0.01); and 1.220 (1.067-1.395), 0.610 (0.513-0.725) and 0.305 (0.248-0.374), respectively (P-trend <0.01), for cumulative dose of metformin. In additional analyses, sulfonylureas but not the other antidiabetic drugs were associated with a reduced risk of ovarian cancer. CONCLUSIONS: Metformin use is associated with a decreased risk of ovarian cancer.
    Date: 2015-09
    Relation: Diabetes Metabolism Research and Reviews. 2015 Sep;31(6):619-626.
    Link to: http://dx.doi.org/10.1002/dmrr.2649
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1520-7552&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000361185200010
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84941259525
    Appears in Collections:[Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB25820555.pdf392KbAdobe PDF357View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback